PF-Atlas › Clinical Trials › NCT05938920

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

INS018_055 · Phase 2

Registry ID
NCT05938920
Phase
Phase 2
Status
Completed
Drug / intervention
INS018_055
Sponsor
InSilico Medicine Hong Kong Limited
Start
2023-06-19
Enrollment
71
Locations
22

About this trial

The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

View NCT05938920 on ClinicalTrials.gov →

Explore related

All INS018_055 trialsAll IPF trials

Related trials

INS018_055 — NCT05154240INS018_055 — NCT05975983
Medical disclaimer. This page summarizes public trial data for NCT05938920 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.